Pharmacy

CBI searches Pharmacy Council of India chief's home over irregularities

A preliminary enquiry by the CBI pointed to suspected manipulation in the inspection and recognition processes for pharmacy colleges across several states, PTI reported

Govt, industry hold talk on issues over marketing code for medical devices

Medical device companies raise issues with the DoP over UDMPMD norms related to disclosure of training expenses and restrictions on overseas training approvals

SastaSundar to invest Rs 150 crore in 2 yrs, aims turnaround in FY26

SastaSundar Ventures Ltd is in the process of investing Rs 150 crore over the next two years to strengthen its digital healthcare platform and warehousing infrastructure to make a turnaround and return to profit in FY'26, a company official said on Thursday. The investment will largely be funded through a Rs 145-crore capital pool, created from the Flipkart Health exit settlement and internal treasury income. The Kolkata-based online pharmacy ended its partnership with Flipkart Health earlier this year and relaunched its B2C platform under its own brand. "We are aiming to return to net profit in the current fiscal through strategic initiatives. We are focusing on the execution of these and capital-efficient growth to recover the company from a Rs 122 crore net loss in FY'25. "Out of the Rs 150 crore, about Rs 40 crore was deployed in FY'25, and the remaining Rs 110 crore will be invested in FY'26 and FY'27," SastaSundar Chairman B L Mittal told PTI. To tap into the rising demand f

AP PGECET 2025 answer key out today at cets.apsche.ap.gov.in; details here

Andhra University has released the Andhra Pradesh Post Graduate Engineering Common Entrance Test (AP PGECET) 2025 answer key today at 4 pm. Candidates can check it at cets.apsche.ap.gov.in/PGECET

Sun Pharma lines up $100 mn to commercialise niche products in FY26

Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating

Zydus Wellness Q4 result: Profit rises 14.4% to Rs 171.9 cr on strong sales

Zydus Wellness Ltd on Monday reported a 14.4 per cent rise in consolidated net profit at Rs 171.9 crore in the fourth quarter ended March 31, 2025, driven by strong performance of its food and nutrition as well as personal care segments. The company had posted a consolidated net profit of Rs 150.3 crore in the same quarter of the previous fiscal. The board of the company has approved the sub-division of its stock with one equity share of face value of Rs 10 to be split into five equity shares of face value Rs 2 each, subject to shareholders' approval. Consolidated total revenue from operations in the fourth quarter stood at Rs 910.6 crore, as compared to Rs 778 crore in the year-ago period, Zydus Wellness Ltd said in a regulatory filing. Total expenses in the quarter under review were higher at Rs 740.5 crore, as compared to Rs 632.2 crore in the corresponding period a year ago. With the continued thrust on marketing initiatives, several key brands including Nutralite, Glucon-D, .

Agri, pharma, electronics, engineering made up 50% of FY25 exports: Govt

Agriculture, pharma, electronics, and engineering goods together accounted for over 50 per cent of India's merchandise exports in 2024-25, according to government data, highlighting the country's growing strength in diverse sectors amid efforts to boost manufacturing and value-added exports. Engineering goods contributed the highest share of 26.67 per cent to India's USD 437.42 billion exports in 2024-25, while agriculture, pharmaceuticals, and electronics accounted for 11.85 per cent, 6.96 per cent, and 8.82 per cent, respectively. The data showed that the electronic goods sector saw the highest export growth rate at 32.46 per cent, jumping from USD 29.12 billion in 2023-24 to USD 38.58 billion in the last fiscal year. It was USD 23.6 billion in 2022-23 and USD 15.7 billion in 2021-22. Within this, computer hardware and peripherals, which form 3.8 per cent of the sector, saw 101 per cent growth, doubling from USD 0.7 billion to USD 1.4 billion. The main destinations for electronic

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

IPA and Ind-Ra say Trump's MFN-based drug pricing move will impact innovators more than Indian generics, with CDMO firms likely to gain from offshore cost advantages

Pharma industry's success relies on innovation, else it will extinct: Goyal

Commerce and Industry Minister Piyush Goyal on Saturday emphasised on the crucial role of innovation in driving the growth of the Indian pharmaceutical industry and warned that without innovation, the industry will be "finished". He also expressed concern that the industry often relies on government incentives to conduct research and development in the sector. "Sadly, our country's mindset has become so weak that for everything we are looking up to the government... we think that only after getting a tax incentive then only we will do research. This is the industry where innovation determines success, whoever will not innovate will be finished," he said, while addressing members of the drug making firms in Mumbai. He also cautioned that if the industry will not innovate, its future is worrisome. The industry will have to keep pace with the changing lifestyle patterns besides demands and needs of the society and patents, Goyal said. He called upon the industry to come forward with

White-collar hiring up 4% in Jan, driven by FMCG, pharma, insurance sectors

White-collar hiring activities in January witnessed 4 per cent growth driven by traditional sectors, including FMCG, pharma and insurance, according to a report released on Monday. "In 2024, January had greeted us with a disappointing 11 per cent de-growth in hiring. In contrast, 2025 seems to have started on a positive note. The 4 per cent hiring growth is tempered as IT recovery settles in, however, strong growth in most core sectors, including FMCG, pharma, insurance and hospitality is a good sign and augurs well for a cracking 2025 in terms of white collar hiring," Naukri Chief Business Officer Pawan Goyal said in a statement quoting NaukriJobSpeak Index. The report revealed a steady hiring environment with strong performances in core sectors like FMCG (16 per cent), insurance (15 per cent), and pharma (11 per cent), and hospitality by 8 per cent, while IT hiring remained flattish, the report added. The Naukri JobSpeak is a monthly index representing the Indian job market and ..

Divi's Lab Q3 result: Profit up 65% to Rs 589 cr on robust market sales

Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the December quarter, on the back of robust sales across markets. The company had reported a profit after tax (PAT) of Rs 358 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 2,319 crore in the third quarter as against Rs 1,855 crore in the year-ago period, Divi's Laboratories said in a regulatory filing. The drug firm noted a part of the Kakinada Project (Unit-III) commenced commercial operations from January 1, 2025. The rest of Kakinada project is being implemented and is expected to be operational in about six months, it added. "We have capitalised assets of Rs 433 crore for the quarter and of Rs 557 crore for the nine-month period of the current fiscal year. Of this, capitalisation for Kakinada Project is Rs 418 crore during the 9-month period," the drug firm stated. The company said its board has approved the re-appointme

Doctors may face suspension in NMC probe over pharma-sponsored trips

This was in violation of the UCPMP rules, which regulate interactions between pharmaceutical companies and HCPs and prohibit foreign trips, gifts, and inducements as unethical marketing practices

India, Belgium discuss ways to enhance trade in pharma, agri products

India and Belgium have agreed to establish mechanisms to resolve trade issues in areas such as pharma and agri products to boost bilateral trade, according to an official statement issued on Tuesday. The issues were discussed during the meeting between Commerce and Industry Minister Piyush Goyal and Belgian Minister of Foreign Affairs and Foreign Trade Bernard Quintin, in Brussels. "Regulatory barriers, particularly in the approval processes for pharmaceuticals and agri-products, were also discussed, with both sides agreeing to tackle these challenges through continuous dialogue," the commerce ministry said. It said that the two ministers agreed to establish stronger mechanisms for resolving trade issues. The leaders also discussed the progress of the EU-India Free Trade Agreement (FTA) talks and emphasised the importance of prioritising trade issues to streamline negotiations and strengthen economic ties. Emerging sectors such as renewable energy, life sciences, infrastructure, .

PAG acquires majority stake in pharma company Pravesha Industries

PAG has been investing in India since 2009 and currently manages over $3 billion in assets in the country

AI, machine learning to help Indian pharma industry to pivot on innovation

As technological advancements like AI, machine learning and precision medicine revolutionise drug discovery, manufacturing and patient care, Indian pharmaceutical industry is set for a 'profound transformation' in 2025 with innovation, wider global access and improvement in quality becoming key themes for the future. The industry, which is expected to grow nearly two-fold to around USD 130 billion in size by 2030, is looking to take advantage of conducive policies, demographic and digital talent, in making India play a pivotal role in advancing global health for all. Currently accounting for around 20 per cent of the overall generic drug sales globally, the Indian pharma industry is focussing on research excellence and innovation in order to position the country as a global hub for high-quality, affordable pharmaceuticals. "The Indian pharma market is expected to move up to USD 120-130 billion by 2030 from the current size of USD 58 billion. Initiatives in terms of quality, innovati

Big Pharma's bet on China biotech a rare trade bright spot amid tensions

Chinese biomedical research is on the cusp of a breakthrough just as the industry starts to face serious headwinds

AstraZeneca raises expectation for next year profits after Q3 performance

AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast of a mid-teens percentage at constant currency rates for both revenue

Indian pharmacopoeia standard used by 11 countries: DCGI Rajeev Raghuvanshi

The WHO-led experts team approved India's vaccine regulatory system after an in-depth scientific review, conducted between September 16 and 20, as per a statement by the Ministry of Health and Family

CVS Health likely to explore options including potential break-up

CVS is led by healthcare industry veteran Karen Lynch, who previously headed the Aetna unit and is temporarily overseeing the business with Chief Financial Officer Tom Cowhey

World Pharmacist Day 2024: Date, History, significance, wishes and quotes

Every year on September 25, 2023, World Pharmacist Day is observed as a special day to honour and acknowledge pharmacists for their enormous contributions to enhancing world health